These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

624 related articles for article (PubMed ID: 21520200)

  • 1. Endpoints and clinical trial design for nonalcoholic steatohepatitis.
    Sanyal AJ; Brunt EM; Kleiner DE; Kowdley KV; Chalasani N; Lavine JE; Ratziu V; McCullough A
    Hepatology; 2011 Jul; 54(1):344-53. PubMed ID: 21520200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials.
    Caussy C; Reeder SB; Sirlin CB; Loomba R
    Hepatology; 2018 Aug; 68(2):763-772. PubMed ID: 29356032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic fatty liver disease: a systematic review.
    Rinella ME
    JAMA; 2015 Jun; 313(22):2263-73. PubMed ID: 26057287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of nonalcoholic fatty liver disease: a 60-year-old man with probable nonalcoholic fatty liver disease: weight reduction, liver biopsy, or both?
    Afdhal NH
    JAMA; 2012 Aug; 308(6):608-16. PubMed ID: 22760235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histological Endpoints for Nonalcoholic Steatohepatitis Trials: Lights and Shadows.
    Rowe IA
    Semin Liver Dis; 2020 Nov; 40(4):339-345. PubMed ID: 32906165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop.
    Sanyal AJ; Friedman SL; McCullough AJ; Dimick-Santos L; ;
    Hepatology; 2015 Apr; 61(4):1392-405. PubMed ID: 25557690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers for early detection of non-alcoholic steatohepatitis: implications for drug development and clinical trials.
    Yilmaz Y
    Curr Drug Targets; 2013 Oct; 14(11):1357-66. PubMed ID: 24020975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis.
    Shi YW; Fan JG
    Clin Mol Hepatol; 2023 Feb; 29(Suppl):S228-S243. PubMed ID: 36521452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic Steatohepatitis: A Review.
    Sheka AC; Adeyi O; Thompson J; Hameed B; Crawford PA; Ikramuddin S
    JAMA; 2020 Mar; 323(12):1175-1183. PubMed ID: 32207804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic steatohepatitis (NASH) cirrhosis: a snapshot of therapeutic agents in clinical development and the optimal design for clinical trials.
    Aggarwal P; Noureddin M; Harrison S; Jeannin S; Alkhouri N
    Expert Opin Investig Drugs; 2022 Feb; 31(2):163-172. PubMed ID: 35060815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH).
    Drescher HK; Weiskirchen S; Weiskirchen R
    Cells; 2019 Aug; 8(8):. PubMed ID: 31394730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Younossi ZM; Loomba R; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Chalasani NP; Anstee QM; Kowdley KV; George J; Goodman ZD; Lindor K
    Hepatology; 2018 Jul; 68(1):361-371. PubMed ID: 29222911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD.
    Rinella ME; Tacke F; Sanyal AJ; Anstee QM;
    Hepatology; 2019 Oct; 70(4):1424-1436. PubMed ID: 31287572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure of proof of concept studies that precede a nonalcoholic steatohepatitis development program.
    Williams RN; Filozof C; Goldstein BJ; Cusi K
    Clin Pharmacol Ther; 2017 Apr; 101(4):444-446. PubMed ID: 28032901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic Fatty Liver Disease vs. Nonalcoholic Steatohepatitis: Pathological and Clinical Implications.
    Boutari C; Lefkos P; Athyros VG; Karagiannis A; Tziomalos K
    Curr Vasc Pharmacol; 2018; 16(3):214-218. PubMed ID: 28676025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.
    Younossi ZM; Loomba R; Anstee QM; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Goodman ZD; Chalasani NP; Kowdley KV; George J; Lindor K
    Hepatology; 2018 Jul; 68(1):349-360. PubMed ID: 29222917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic fatty liver disease: a clinical review.
    Sass DA; Chang P; Chopra KB
    Dig Dis Sci; 2005 Jan; 50(1):171-80. PubMed ID: 15712657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonalcoholic Fatty Liver Disease: A Silent Epidemic.
    Sivell C
    Gastroenterol Nurs; 2019; 42(5):428-434. PubMed ID: 31574071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of the ELF Test for Detecting Steatohepatitis in Morbid Obese Patients with Suspicion of Nonalcoholic Fatty Liver Disease.
    López IC; Aroca FG; Bernal MDF; Mompeán JAL; Bernal ÁB; Martínez AMH; Barba EM; Velasco JAN; Paricio PP
    Obes Surg; 2017 Sep; 27(9):2347-2353. PubMed ID: 28229316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Features, diagnosis, and treatment of nonalcoholic fatty liver disease.
    Torres DM; Williams CD; Harrison SA
    Clin Gastroenterol Hepatol; 2012 Aug; 10(8):837-58. PubMed ID: 22446927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.